Skip to search boxSkip to navigationSkip to main content

AI, mRNA platforms, and the pandemic crisis: key accelerators of a shift toward disruptive business models and transformed trajectories in the global COVID-19 vaccine ecosystem (2020–2023)

Student thesis:
Student thesis
Doctoral Thesis

About the thesis

The COVID-19 pandemic profoundly affected biotechnology organisations, which were leading the development of solutions during the global pandemic crisis. By shortening development timelines and forcing rapid adjustments in innovation and production systems, many vaccine companies joined the race for the first impactful vaccine to stop the propagation. This study examines how biotechnology business models have undergone a fast transformation under global crisis conditions by comparing case studies of three COVID-19 vaccine manufacturers: INOVIO, Moderna, and BioNTech. The research aims to show how biotech platforms, combined with AI/LLM, caused internal disruptions and fast-tracked new vaccine pathways. The business models are influenced by both external disruptions from the pandemic and internal changes driven by new technologies, crisis-driven collaboration, and regulatory adjustments, which reshape value creation and competitive advantage within vaccine ecosystems.
This study uses a qualitative, exploratory-explanatory research design, along with an interpretivist–pragmatist philosophy and a comparative multiple-case study approach. It combines a systematic literature review, documentary and regulatory analysis, semi-structured expert interviews, and digital and social media materials, which are analysed through inductive, pattern-based thematic analysis.
Five key elements leading to business model disruption are identified through the empirical analysis of the study: (1) securing funding from diverse sources despite high levels of uncertainty; (2) adopting digital and AI-driven innovation capabilities; (3) generating and leveraging ecosystem partnerships; (4) expanding reach within the global market; and (5) increasing organisational agility through platform orchestration. The results show that platform-based business models can accelerate sectoral transformation. In addition to the impact of platform-based business models, rapid technological progress in biotechnology research and ecosystem-level coordination are crucial for their success. Ongoing challenges related to market access, regulation, and systemic complexity can still hinder and delay these efforts.
This research makes a theoretical contribution to the fields of disruptive innovation, crisis management, and innovative biotechnology business models by offering an integrated analytical approach that links platform technology strategy, institutional context, and collaborative partnerships in a crisis setting during the global pandemic. Conceptually, it enhances understanding of how crisis-induced disruptions serve as catalysts for reconfiguring business models within vaccine ecosystems. The research results provide evidence-based insights for industry leaders, policymakers, and researchers in health care and pharmaceuticals on how to align innovative platform strategies with public health goals to create both commercial value and societal benefits.

Thesis information

Thesis Award Date

09/2026

Qualification Level

Doctoral Thesis

Original Language

English

Supervisors

Nick Marshall (Supervisor), School of Business and Law
Hamid Salimian (Supervisor), School of Business and Law
George Tsekouras (Supervisor)

Awarding Institution

Thesis documents